Saturday 17 October 2026
Export SXTP’s income statement to Excel — free account
60 Degrees Pharmaceuticals Inc.
SXTP Healthcare Biotechnology
60 Degrees Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 106.8% from fiscal 2024. In the quarter to June 2026, revenue fell 32.5%, EPS grew 82.0% and free cash flow fell 54.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.86
0.04
−4.44%
Follow SXTP
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | |
|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 5 | 3 | 3 | — | — |
P/S ratio |
0.97 | 4.32 | 16.08 | 25.28 | 25.28 | 25.28 |
Altman Z-Score |
(15.91) | (13.55) | (6.52) | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(33.29) | (27.73) | (12.69) | (197.89) | (56.80) | (23.50) |
Beneish M-Score |
(2.31) | (4.62) | — | (19.24) | (13.42) | — |
P/Operating CF |
(0.80) | (1.80) | (64.03) | (35.47) | (35.47) | (35.47) |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
(0.12) | 1.14 | 12.45 | 28.01 | 28.01 | 28.01 |
EV/EBITDA |
0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.02 | (0.14) | (0.69) | (11.21) | (11.21) | (11.21) |
EV/FCF |
0.02 | (0.13) | (0.68) | (10.76) | (10.76) | (10.76) |
Quick Ratio |
1.77 | 2.34 | 0.84 | 0.01 | 0.41 | 0.73 |
Current Ratio |
2.66 | 3.25 | 2.55 | 0.05 | 1.85 | 1.70 |
Net Debt/EBITDA |
0.37 | 0.56 | 0.64 | (10.11) | (41.47) | (48.69) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 415.23% | 1,340.47% | 736.50% |
Debt/Equity |
0.00 | 0.00 | 0.00 | (0.22) | (1.03) | (1.10) |
Asset Turnover |
0.25 | 0.10 | 0.06 | 0.38 | 3.18 | 0.00 |
Operating CF/Net income |
0.93 | 0.71 | 1.21 | 0.16 | 0.15 | 0.06 |
Capex/Depreciation |
(0.84) | (0.05) | (0.06) | (0.05) | (0.05) | 0.00 |
Interest Coverage |
(994.69) | (1,229.77) | (2.25) | (0.44) | (0.35) | (0.31) |
| 124.83% | 148.93% | 25.78% | 29.23% | 23.85% | 0.00% | |
| (132.40%) | (117.36%) | (82.94%) | (459.49%) | (212.61%) | 0.00% | |
ROIC |
(771.42%) | (1,070.52%) | (121.31%) | 0.00% | (171.52%) | 0.00% |
Return on Tangible Assets |
(223.25%) | (204.88%) | (84.34%) | 27.11% | (720.50%) | (280.12%) |
Average Days of Receivables |
132.00 | 260.74 | 332.90 | 32.84 | 8.41 | 123.04 |
Research and Development Expense of Revenue |
149.47% | 731.91% | 272.79% | 102.82% | 86.75% | 31.64% |
Selling, General and Administrative Expense of Revenue |
445.66% | 737.59% | 1,672.63% | 255.03% | 17.56% | 57.18% |
Intangible Assets out of Total Assets |
0.04 | 0.03 | 0.03 | 0.13 | 0.08 | 0.03 |
Share Based Compensation of Revenue |
19.86% | 4.81% | 356.78% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
2.14 | 1.22 | 1.04 | (2.21) | (2.21) | (2.21) |
Graham Number |
48.31 | 284.49 | 1,908.07 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(553.22%) | (283.19%) | (213.45%) | (86.59%) | (86.59%) | (86.59%) |
Free Cash Flow Yield |
(519.60%) | (198.19%) | (114.22%) | (10.30%) | (10.30%) | (10.30%) |
Revenue per Share |
2.10 | 5.98 | 15.37 | 51.64 | 1.10 | 0.44 |
Operating CF per Share |
(10.22) | (49.54) | (275.33) | (102.02) | (0.11) | (0.03) |
Capex per Share |
(0.33) | (1.59) | (7.02) | (6.08) | (0.01) | 0.00 |
Free Cash Flow per Share |
(10.55) | (51.13) | (282.35) | (108.10) | (0.12) | (0.03) |
Cash per Share |
4.11 | 29.72 | 129.85 | 26.76 | 0.02 | 0.03 |
Shareholders Equity per Share |
5.04 | 34.69 | 290.79 | (2,439.30) | (3.14) | (3.03) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.04 | 34.69 | 290.79 | (2,439.30) | (3.14) | (3.03) |
Free Cash Flow |
(7.07) | (5.83) | (4.66) | (1.07) | (0.68) | (0.17) |
Working Capital |
3.05 | 3.73 | 4.41 | (22.82) | 0.54 | 1.01 |
Capital Expenditures |
(0.22) | (0.18) | (0.12) | (0.06) | (0.04) | (0.07) |
Net Current Asset Value |
2.91 | 3.58 | 4.26 | (24.35) | (18.37) | (18.23) |
EV/EBIT |
0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.15 | 0.27 | 0.46 | 0.12 | 0.01 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
1.05 | 24.30 | 31.69 | 58.39 | 13.83 | 0.38 |
Cash ROIC |
(115.28%) | (79.39%) | (67.12%) | 5.79% | (106.89%) | (8.88%) |
Accounts Receivable Turnover |
2.83 | 1.90 | 1.83 | 5.31 | 12.63 | 0.00 |
Accounts Payable Turnover |
0.63 | 0.51 | 0.75 | 0.64 | 0.87 | 0.00 |
Inventory Turnover |
1.42 | 0.85 | 0.96 | 0.72 | 0.98 | 0.00 |
Average Days of Payables |
681.39 | 955.75 | 389.30 | 640.44 | 252.59 | 714.94 |
Days of Inventory on Hand |
306.73 | 420.02 | 358.54 | 437.76 | 295.62 | 539.76 |
Average Receivables |
0.50 | 0.36 | 0.14 | 0.10 | 0.50 | — |
Average Payables |
1.23 | 0.76 | 0.63 | 0.67 | 0.98 | — |
Average Inventory |
0.55 | 0.45 | 0.49 | 0.60 | 0.86 | — |
Average Assets |
5.56 | 6.77 | 4.54 | 1.35 | 2.00 | — |
Average Common Equity |
(5.90) | (5.34) | (14.60) | (21.15) | (17.83) | — |
Columns are period end dates